Skip to main content

Milestone Pharmaceuticals Inc.

corporate_fare Company Profile

Milestone Pharmaceuticals Inc.

MIST·NASDAQ·Life Sciences·CIK 0001408443

Milestone Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative cardiovascular medicines. The company's approved product, CARDAMYST™ (etripamil) nasal spray, is available in the United States. This product is the first and only FDA-approved self-administered treatment for patients to use anywhere, anytime an attack of paroxysmal supraventricular tachycardia (PSVT) occurs. Milestone Pharmaceuticals Inc. is also pursuing marketing approval for CARDAMYST™ in regions outside the United States, either directly or through partnerships. The company is also developing etripamil for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals Inc. focuses its efforts and financial resources on three main areas: the commercialization of CARDAMYST™ (etripamil) nasal spray for PSVT, the development of etripamil for AFib-RVR, and corporate development activities aimed at increasing company value through strategic collaborations. On December 12, 2025, the FDA approved CARDAMYST™ (etripamil) nasal spray as a prescription medication for converting acute symptomatic episodes of PSVT to sinus rhythm in adults. This product became available in retail pharmacies in the first quarter of 2026. Milestone Pharmaceuticals Inc. manufactures CARDAMYST™ using a global supply chain that produces the active pharmaceutical ingredient, etripamil, formulates and assembles it into a nasal spray delivery device, and then packages the product. A third-party logistics provider distributes the product to wholesalers for delivery to retail pharmacies. The company's sales team of approximately 60 representatives aims to engage healthcare providers who are expected to treat around 500,000 patients diagnosed with PSVT in 2026. Milestone Pharmaceuticals Inc. designed the etripamil molecule and is commercializing and further developing this novel, potent, and rapid-onset calcium channel blocker as a patient-administered nasal spray to terminate episodes of transient cardiovascular conditions.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for MIST at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for MIST spans 8-K, 10-Q, S-3, 10-K.

Recent high-impact activity:

  • Milestone Posts Wider-Than-Expected Q3 Revenue, Narrows Loss to 18 Cents a Share
  • Milestone Q3: CFO and CMO Out, 30% Cost Cut, RTW PIK Extended to 2029
  • Milestone Cuts 30% of Costs, Extends Cash Runway to Late 2028 as CFO and CMO Exit
  • Milestone Posts $80.5M Nine-Month Loss, Cuts 20% of Staff to Extend Runway
  • Milestone Receives Nasdaq Bid-Price Deficiency Notice, 180 Days to April 21, 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$63.06M
Diluted EPS
-$0.75
Op. Cash Flow
-$49.04M
Free Cash Flow
-$49.34M
Operating Income
-$62.14M
Cash & Equivalents
$73.05M
Total Debt
$57.19M
Debt / Equity
1.37×
Shares Outstanding
106.24M sh
Source: 10-K · filed 2026-03-20 · accession 0001104659-26-032415

Short Interest & Short Volume

24.83 days to cover

FINRA reported short interest of 19,895,670 shares in MIST as of the October 30, 2026 settlement, a 0.9% increase from the prior period — about 24.8 days to cover at its recent average daily volume. On November 13, 2026, 56.9% of MIST volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)19,895,670 shares as of October 30, 2026
Change vs prior period▲ 0.9%
Days to cover24.83 at avg daily volume of 801,259
Daily short volume (FINRA facilities)56.9% of 2,492,371 shares on November 13, 2026
5-day average short volume25.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for MIST, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.

Equity Incentive Plan Expanded · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$0.505 -2.88% today
52-week range · as of 2026-11-13 $0.505 – $3.06
Market cap
$64.74M
Volume
4.2M (3.2× avg)
3-mo avg 1.3M
Live data · 2026-11-16 02:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MIST - Latest Insights

MIST
Nov 13, 2026, 9:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.700
Real-time Price: $0.505 info
Change: -$0.195 (-28%) info
Market Cap: $64.739M info
MIST
Nov 13, 2026, 7:36 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6999
Real-time Price: $0.505 info
Change: -$0.1949 (-28%) info
Market Cap: $64.739M info
MIST
Nov 13, 2026, 7:08 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7201
Real-time Price: $0.505 info
Change: -$0.2151 (-30%) info
Market Cap: $64.739M info
MIST
Nov 13, 2026, 6:49 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.6988
Real-time Price: $0.505 info
Change: -$0.1938 (-28%) info
Market Cap: $64.739M info
MIST
Oct 28, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.755349
Real-time Price: $0.505 info
Change: -$0.250349 (-33%) info
Market Cap: $64.739M info
MIST
Sep 03, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.505 info
Change: -$0.705 (-58%) info
Market Cap: $64.739M info
MIST
Sep 03, 2026, 10:47 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.505 info
Change: -$0.7241 (-59%) info
Market Cap: $64.739M info
MIST
Aug 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $0.505 info
Change: -$0.555 (-52%) info
Market Cap: $64.739M info
MIST
Aug 12, 2026, 7:28 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.505 info
Change: -$0.595 (-54%) info
Market Cap: $64.739M info
MIST
Aug 12, 2026, 7:08 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.505 info
Change: -$0.625 (-55%) info
Market Cap: $64.739M info
MIST
Aug 12, 2026, 7:01 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.505 info
Change: -$0.595 (-54%) info
Market Cap: $64.739M info
MIST
Jun 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.34
Real-time Price: $0.505 info
Change: -$0.835 (-62%) info
Market Cap: $64.739M info
MIST
May 14, 2026, 3:54 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.505 info
Change: -$1.15 (-69%) info
Market Cap: $64.739M info
MIST
May 13, 2026, 5:28 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.73
Real-time Price: $0.505 info
Change: -$1.23 (-71%) info
Market Cap: $64.739M info
MIST
May 13, 2026, 7:04 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $0.505 info
Change: -$1.38 (-73%) info
Market Cap: $64.739M info
MIST
Apr 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.09
Real-time Price: $0.505 info
Change: -$1.59 (-76%) info
Market Cap: $64.739M info
MIST
Mar 20, 2026, 7:12 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.72
Real-time Price: $0.505 info
Change: -$1.21 (-71%) info
Market Cap: $64.739M info
MIST
Mar 20, 2026, 7:07 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.77
Real-time Price: $0.505 info
Change: -$1.27 (-71%) info
Market Cap: $64.739M info
MIST
Jan 28, 2026, 6:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $1.96
Real-time Price: $0.505 info
Change: -$1.46 (-74%) info
Market Cap: $64.739M info
MIST
Jan 26, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.00
Real-time Price: $0.505 info
Change: -$1.50 (-75%) info
Market Cap: $64.739M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets